Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven breast carcinoma evaluated for HER 2 status and immune status~* Locally advanced carcinoma (UICC stage II-III)~* Age \< 70 years~* measurable lesions~* ECOG Performance Status 0-2~* Life expectancy \> 3 months~* Adequate bone marrow and hepatic functions~* Creatinine Clearance \> 40 ml/min~* Written informed consent~* Patients must be accessible for treatment and follow up.~Exclusion Criteria:~* Prior chemotherapy or hormonal treatments~* Brain metastases.~* Past or current history of neoplasm other than curatively treated.~* Concurrent treatment with other experimental drugs.~* Left Ventricular Ejection Fraction (LVEF) \<50 %~* History of significant neurological or psychiatric disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Locally advanced HER2+ breast cancer pts (Type: EXPERIMENTAL): HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision
- Locally advanced HER2- breast cancer pts (Type: EXPERIMENTAL): HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision.

Based on this trial design, predict the completion outcome and termination type (if applicable).